FPR2 and malignant colon neoplasm: The distribution of the formyl peptide receptor is not limited to phagocytosis of leukocytes but is also expressed in tumor cells such as colon cancer, which enhances drug resistance, and knockdown of FPR2 reduces the tumorigenicity of colon cancer [8, 9].